Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8 + T  cell augmentation

ConclusionsThe studies indicate that PYM, as an ICD inducer with mild myelosuppression effect, may enhance the therapeutic efficacy of anti-PD-1 antibody in association with tumor infiltrating CD8+ T cell augmentation.

Source: Cancer Chemotherapy and Pharmacology - January 3, 2021 Category: Cancer & Oncology Source Type: research